ATE339425T1 - Platelet adp rezeptor inhibitoren - Google Patents
Platelet adp rezeptor inhibitorenInfo
- Publication number
- ATE339425T1 ATE339425T1 AT02750339T AT02750339T ATE339425T1 AT E339425 T1 ATE339425 T1 AT E339425T1 AT 02750339 T AT02750339 T AT 02750339T AT 02750339 T AT02750339 T AT 02750339T AT E339425 T1 ATE339425 T1 AT E339425T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- receptor inhibitors
- adp receptor
- platelet adp
- formulae
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/920,325 US6906063B2 (en) | 2000-02-04 | 2001-08-02 | Platelet ADP receptor inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE339425T1 true ATE339425T1 (de) | 2006-10-15 |
Family
ID=25443563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02750339T ATE339425T1 (de) | 2001-08-02 | 2002-07-25 | Platelet adp rezeptor inhibitoren |
AT06015189T ATE485290T1 (de) | 2001-08-02 | 2002-07-25 | Platelet adp rezeptor inhibitoren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06015189T ATE485290T1 (de) | 2001-08-02 | 2002-07-25 | Platelet adp rezeptor inhibitoren |
Country Status (12)
Country | Link |
---|---|
US (7) | US6906063B2 (de) |
EP (3) | EP2314593B1 (de) |
JP (2) | JP4648626B2 (de) |
AT (2) | ATE339425T1 (de) |
CA (1) | CA2468925A1 (de) |
CY (1) | CY1112024T1 (de) |
DE (2) | DE60238086D1 (de) |
DK (1) | DK1734041T3 (de) |
ES (2) | ES2354708T3 (de) |
HK (3) | HK1064099A1 (de) |
PT (1) | PT1734041E (de) |
WO (1) | WO2003011872A1 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254336A1 (de) * | 2002-11-21 | 2004-06-03 | Merck Patent Gmbh | Carbonsäureamide |
KR20060041254A (ko) * | 2003-07-24 | 2006-05-11 | 아스텔라스세이야쿠 가부시키가이샤 | 퀴놀론 유도체 또는 그의 염 |
KR20060113699A (ko) * | 2003-10-03 | 2006-11-02 | 포톨라 파마슈티컬스, 인코포레이티드 | 치환된 이소퀴놀리논 |
KR20060113700A (ko) * | 2003-10-03 | 2006-11-02 | 포톨라 파마슈티컬스, 인코포레이티드 | 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아 |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US7205296B2 (en) * | 2004-09-29 | 2007-04-17 | Portola Pharmaceuticals, Inc. | Substituted 2H-1,3-benzoxazin-4(3H)-ones |
US20090227555A2 (en) * | 2005-01-06 | 2009-09-10 | Astrazeneca Ab | Novel Pyridine Compounds |
JP2008527043A (ja) * | 2005-01-19 | 2008-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓塞栓障害治療用のp2y1受容体阻害剤としての2−フェノキシ−n−(1,3,4−チアジアゾール−2−イル)ピリジン−3−アミン誘導体および関連化合物 |
ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
US7728008B2 (en) * | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
EP1899299B1 (de) * | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
US7714002B2 (en) * | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
ATE502924T1 (de) * | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
AU2006267148A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
ATE540034T1 (de) * | 2005-11-03 | 2012-01-15 | Portola Pharm Inc | Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren |
WO2007131179A1 (en) | 2006-05-05 | 2007-11-15 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
JP2009538860A (ja) * | 2006-06-01 | 2009-11-12 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾール誘導体 |
TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
KR20090020712A (ko) * | 2006-07-04 | 2009-02-26 | 아스트라제네카 아베 | 신규한 피리딘 유도체 |
TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
KR20090036573A (ko) * | 2006-07-04 | 2009-04-14 | 아스트라제네카 아베 | 신규한 피리딘 유사체 |
CN101506193A (zh) * | 2006-07-04 | 2009-08-12 | 阿斯利康(瑞典)有限公司 | 新吡啶类似物 |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7834023B2 (en) * | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
CL2008000092A1 (es) * | 2007-01-12 | 2008-09-05 | Astrazeneca Ab | Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria. |
UY30868A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones. |
JP2010515728A (ja) * | 2007-01-12 | 2010-05-13 | アストラゼネカ アクチボラグ | ピリジン化合物及びp2y12アンタゴニストとしてのその使用(新規なピリジン類似体ix519) |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
MX2009007831A (es) | 2007-01-22 | 2010-01-15 | Gtx Inc | Agentes de union de receptor nuclear. |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
JPWO2008133155A1 (ja) * | 2007-04-19 | 2010-07-22 | アステラス製薬株式会社 | 二環式ヘテロ環化合物 |
CN101720324A (zh) * | 2007-05-02 | 2010-06-02 | 波托拉医药品公司 | [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法 |
CA2686203A1 (en) | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
CN101686959B (zh) * | 2007-05-02 | 2014-05-07 | 波托拉医药品公司 | 作为血小板adp受体抑制剂的化合物的组合疗法 |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
AR064865A1 (es) * | 2007-07-13 | 2009-04-29 | Astrazeneca Ab | Derivados de piridina antagonistas de p2y12 |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2011075602A1 (en) * | 2009-12-17 | 2011-06-23 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
EP2513094B1 (de) * | 2009-12-17 | 2015-12-16 | Millennium Pharmaceuticals, Inc. | Salze und kristalline formen eines faktor-xa-inhibitors |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN103833724A (zh) * | 2012-11-20 | 2014-06-04 | 上海医药工业研究院 | 一种5-氯噻吩-2-甲酰氯的制备方法 |
CN103833771A (zh) * | 2012-11-22 | 2014-06-04 | 天津滨江药物研发有限公司 | 作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途 |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
MA47440B1 (fr) | 2015-02-16 | 2021-08-31 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées, composés apparentés, et leur utilisation |
EP3359526A4 (de) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | Aktivatoren von autophagischem fluss und phospholipase d und reinigung von proteinaggregaten einschliesslich tau und behandlung von proteinopathien |
WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
JP7235742B2 (ja) | 2017-07-07 | 2023-03-08 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
CN117143042A (zh) | 2017-07-24 | 2023-12-01 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
CA3071150A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
EP3668842A1 (de) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
WO2019092170A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
EP3759077A1 (de) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Neuartige verbindungen |
BR112022002609A2 (pt) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | Métodos de tratamento de tumores estromais gastrointestinais |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
WO2021048809A1 (en) * | 2019-09-12 | 2021-03-18 | Cadila Healthcare Limited | Novel substituted sulfoximine derivatives |
DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE845042C (de) * | 1950-07-14 | 1952-07-28 | Basf Ag | Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden |
US3547625A (en) * | 1966-08-25 | 1970-12-15 | Int Nickel Co | Steel containing chromium molybdenum and nickel |
US3847925A (en) | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
US5614539A (en) * | 1993-03-15 | 1997-03-25 | G. D. Searle & Co. | Urea compounds which are useful as platelet aggregation inhibitors |
TW448161B (en) | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
JPH0881442A (ja) * | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
US6413724B1 (en) * | 1996-10-28 | 2002-07-02 | Versicor, Inc. | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones |
JPH10195323A (ja) * | 1997-01-09 | 1998-07-28 | Nippon Paper Ind Co Ltd | 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体 |
EP1047699A1 (de) | 1998-01-15 | 2000-11-02 | Cor Therapeutics, Inc. | Platelet adp rezeptor inhibitoren |
JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
DE60114994T2 (de) | 2000-02-04 | 2006-08-03 | Portola Pharmaceuticals, Inc., South San Francisco | Blutplättchen-adp-rezeptor-inhibitoren |
MXPA03011951A (es) * | 2001-06-20 | 2004-03-26 | Daiichi Seiyaku Co | Derivados de diamina. |
-
2001
- 2001-08-02 US US09/920,325 patent/US6906063B2/en not_active Expired - Fee Related
-
2002
- 2002-07-25 WO PCT/US2002/023909 patent/WO2003011872A1/en active IP Right Grant
- 2002-07-25 DE DE60238086T patent/DE60238086D1/de not_active Expired - Lifetime
- 2002-07-25 DE DE60214730T patent/DE60214730T2/de not_active Expired - Lifetime
- 2002-07-25 ES ES06015189T patent/ES2354708T3/es not_active Expired - Lifetime
- 2002-07-25 CA CA002468925A patent/CA2468925A1/en not_active Abandoned
- 2002-07-25 ES ES02750339T patent/ES2272742T3/es not_active Expired - Lifetime
- 2002-07-25 EP EP10183633.6A patent/EP2314593B1/de not_active Expired - Lifetime
- 2002-07-25 JP JP2003517063A patent/JP4648626B2/ja not_active Expired - Fee Related
- 2002-07-25 AT AT02750339T patent/ATE339425T1/de not_active IP Right Cessation
- 2002-07-25 PT PT06015189T patent/PT1734041E/pt unknown
- 2002-07-25 DK DK06015189.1T patent/DK1734041T3/da active
- 2002-07-25 EP EP06015189A patent/EP1734041B1/de not_active Expired - Lifetime
- 2002-07-25 AT AT06015189T patent/ATE485290T1/de active
- 2002-07-25 EP EP02750339A patent/EP1412364B1/de not_active Expired - Lifetime
-
2004
- 2004-09-10 HK HK04106901A patent/HK1064099A1/xx not_active IP Right Cessation
- 2004-09-10 HK HK07102667.1A patent/HK1096088A1/xx not_active IP Right Cessation
- 2004-09-13 US US10/941,053 patent/US7056926B2/en not_active Expired - Lifetime
-
2005
- 2005-12-01 US US11/293,026 patent/US7358257B2/en not_active Expired - Fee Related
-
2007
- 2007-08-20 US US11/841,711 patent/US7622474B2/en not_active Expired - Fee Related
-
2009
- 2009-09-14 US US12/559,389 patent/US8067428B2/en not_active Expired - Fee Related
-
2010
- 2010-03-29 JP JP2010076428A patent/JP2010155860A/ja active Pending
-
2011
- 2011-01-07 CY CY20111100028T patent/CY1112024T1/el unknown
- 2011-10-10 US US13/270,193 patent/US8524721B2/en not_active Expired - Fee Related
- 2011-10-27 HK HK11111603.3A patent/HK1157331A1/zh not_active IP Right Cessation
-
2013
- 2013-07-31 US US13/956,251 patent/US20140221405A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1734041T3 (da) | Inhibitorer for receptoren for ADP-blodplader | |
DE60114994D1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
DK1487444T3 (da) | Anvendelse af pyridylamider som angiogeneseinhibitorer | |
EA200801245A1 (ru) | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
DE60330187D1 (de) | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen | |
DE60324544D1 (de) | Muskarin antagonisten | |
NO20032233L (no) | Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer | |
ATE361288T1 (de) | N-(3,-dimethylindolin-6-yl)ä2-ä(4- | |
ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
NO2007010I2 (no) | Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
ITRM990338A0 (it) | Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria. | |
NO20050664L (no) | 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer | |
MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
ID25478A (id) | Agonis 5-ht1f | |
ITMI20011284A0 (it) | Composizione farmaceutica per il trattamento dell'iperfosfatemia | |
DE602004028113D1 (de) | Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung | |
ATE327240T1 (de) | 2ß OXO-VORUSCHARIN UND DERIVATEN | |
PT1370526E (pt) | Diamidas que inibem a actividade da triptase e do factor xa | |
ITMI20011378A0 (it) | Composizione farmaceutica per il trattamento dell'iperfosfatemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |